ELPHALOR Trademark

Trademark Overview


On Monday, December 10, 2018, a trademark application was filed for ELPHALOR with the United States Patent and Trademark Office. The USPTO has given the ELPHALOR trademark a serial number of 88223035. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 14, 2020. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The ELPHALOR trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ...
elphalor

General Information


Serial Number88223035
Word MarkELPHALOR
Filing DateMonday, December 10, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 14, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 12, 2019

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations, namely, oral and injectable contraceptives, women's hormone replacement medications

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, January 2, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNorth Wales, PA 19454

Trademark Events


Event DateEvent Description
Monday, December 14, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, December 14, 2020ABANDONMENT - NO USE STATEMENT FILED
Wednesday, May 6, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 4, 2020EXTENSION 2 GRANTED
Monday, May 4, 2020EXTENSION 2 FILED
Monday, May 4, 2020TEAS EXTENSION RECEIVED
Tuesday, November 5, 2019TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, November 7, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 5, 2019EXTENSION 1 GRANTED
Tuesday, November 5, 2019EXTENSION 1 FILED
Tuesday, November 5, 2019TEAS EXTENSION RECEIVED
Tuesday, May 7, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 12, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 12, 2019PUBLISHED FOR OPPOSITION
Wednesday, February 20, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 29, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, January 29, 2019ASSIGNED TO EXAMINER
Wednesday, January 2, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, December 13, 2018NEW APPLICATION ENTERED IN TRAM